Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging
- 24 October 2006
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 104 (1) , 87-91
- https://doi.org/10.1007/s10549-006-9394-6
Abstract
Arthralgia, skeletal and muscle pain have been reported in postmenopausal women under treatment with third generation aromatase inhibitors (AIs). However, the pathogenesis and anatomic correlate of musculoskeletal pains have not been thoroughly evaluated. Moreover, the impact of AI-induced musculoskeletal symptoms on normal daily functioning needs to be further explored.Keywords
This publication has 17 references indexed in Scilit:
- Management of Cancer-Treatment–Induced Bone Loss in Postmenopausal Women Undergoing Adjuvant Breast Cancer Therapy: A Z-FAST UpdateSeminars in Oncology, 2006
- Aromatase inhibitors as adjuvant treatment of breast cancerCritical Reviews in Oncology/Hematology, 2006
- A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast CancerNew England Journal of Medicine, 2005
- Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivationArthritis & Rheumatism, 2005
- Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trialThe Lancet, 2005
- Switching to Anastrozole Versus Continued Tamoxifen Treatment of Early Breast Cancer: Preliminary Results of the Italian Tamoxifen Anastrozole TrialJournal of Clinical Oncology, 2005
- Safety Considerations of Adjuvant Therapy in Early Breast Cancer in Postmenopausal WomenOncology, 2005
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerNew England Journal of Medicine, 2004
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast CancerNew England Journal of Medicine, 2003
- Risks versus benefits in the clinical application of aromatase inhibitors.Endocrine-Related Cancer, 1999